RNA biology

New RNA-based treatments for brain and muscle diseases

Updated

Abstract

RNA therapeutics may offer new treatment options for human diseases, including central nervous system disorders.

  • RNA-based drugs, such as antisense oligonucleotides and small interfering RNAs, can target diseases currently resistant to traditional therapies.
  • These therapeutics could modulate entire disease pathways, indicating a new approach for developing disease-modifying treatments.
  • Strategies for delivering RNA drugs to the central nervous system are under investigation, with recent advances noted in clinical developments.
  • Current research focuses on the application of ASO drugs and siRNA-based therapeutics for neurological and neuromuscular disorders.

Simplified

Key numbers

7
Approved RNA Drugs
Approved by FDA and EMA for various conditions.
27
Clinical Trials
Ongoing trials indicate active development in this field.

Full Text

What this is

  • RNA therapeutics offer a new approach to treating neurological and neuromuscular diseases.
  • They include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that target previously undruggable pathways.
  • The review discusses delivery methods and recent clinical developments of these RNA-based therapies.

Essence

  • RNA therapeutics, particularly ASOs and siRNAs, represent a promising strategy for treating neurological and neuromuscular diseases by targeting disease pathways that traditional drugs cannot.

Key takeaways

  • RNA therapeutics can selectively target disease pathways, offering potential disease-modifying treatments for conditions like spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).
  • Challenges remain in effectively delivering RNA drugs to the central nervous system (CNS), necessitating innovative delivery methods to ensure therapeutic efficacy.
  • Recent clinical trials have shown promise, with several RNA drugs approved or in advanced stages for various neurological disorders, indicating a significant shift in treatment paradigms.

Caveats

  • Despite advancements, the delivery of RNA therapeutics to the CNS is still a major hurdle, and further research is needed to optimize these methods.
  • The long-term effects and potential adverse reactions of RNA-based therapies require careful monitoring and additional studies to ensure patient safety.

Simplified

Funding

Competing interests

S.N.H. is an employee and H.K. and S.K. are scientific cofounders of Neumirna Therapeutics, a biopharmaceutical company developing RNA-based therapeutics for neurological disorders and have shares in the company. A.H. declares no competing interests. The figures were created with BioRender.com.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free